Kopran Ltd
Kopran Ltd. is a fully integrated pharmaceutical company that manufactures and supplies high-quality formulations and active pharmaceutical ingredients globally.
- Market Cap ₹ 922 Cr.
- Current Price ₹ 191
- High / Low ₹ 370 / 155
- Stock P/E 23.9
- Book Value ₹ 107
- Dividend Yield 1.56 %
- ROCE 9.75 %
- ROE 7.64 %
- Face Value ₹ 10.0
Pros
- Company has been maintaining a healthy dividend payout of 39.7%
Cons
- The company has delivered a poor sales growth of 11.9% over past five years.
- Company has a low return on equity of 8.32% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
303 | 326 | 296 | 310 | 313 | 358 | 360 | 492 | 478 | 551 | 615 | 630 | |
260 | 294 | 266 | 274 | 283 | 312 | 313 | 410 | 390 | 499 | 540 | 557 | |
Operating Profit | 43 | 31 | 30 | 36 | 31 | 46 | 47 | 82 | 87 | 52 | 74 | 73 |
OPM % | 14% | 10% | 10% | 12% | 10% | 13% | 13% | 17% | 18% | 9% | 12% | 12% |
2 | -48 | 1 | 11 | 9 | 3 | -0 | 18 | 11 | 3 | 15 | 4 | |
Interest | 14 | 13 | 13 | 14 | 9 | 9 | 9 | 6 | 5 | 6 | 9 | 9 |
Depreciation | 13 | 10 | 8 | 8 | 9 | 9 | 10 | 10 | 11 | 13 | 13 | 16 |
Profit before tax | 17 | -39 | 11 | 25 | 23 | 32 | 28 | 83 | 82 | 36 | 68 | 52 |
Tax % | 0% | 0% | 0% | 20% | 10% | 24% | 26% | 26% | 25% | 24% | 25% | 26% |
17 | -39 | 11 | 20 | 20 | 24 | 21 | 62 | 61 | 27 | 51 | 39 | |
EPS in Rs | 4.40 | -9.52 | 2.48 | 4.60 | 4.74 | 5.55 | 4.86 | 14.24 | 12.66 | 5.65 | 10.57 | 7.99 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 21% | 24% | 53% | 28% | 38% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 12% |
3 Years: | 10% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | 12% |
3 Years: | -14% |
TTM: | -24% |
Stock Price CAGR | |
---|---|
10 Years: | 14% |
5 Years: | 46% |
3 Years: | -6% |
1 Year: | -24% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 12% |
3 Years: | 8% |
Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 39 | 41 | 43 | 43 | 43 | 43 | 43 | 43 | 48 | 48 | 48 | 48 |
Reserves | 67 | 49 | 57 | 81 | 101 | 125 | 146 | 202 | 378 | 391 | 443 | 470 |
137 | 86 | 80 | 95 | 89 | 97 | 88 | 66 | 75 | 75 | 99 | 148 | |
56 | 99 | 84 | 78 | 82 | 85 | 92 | 128 | 110 | 135 | 153 | 178 | |
Total Liabilities | 299 | 275 | 264 | 298 | 315 | 351 | 370 | 439 | 611 | 650 | 743 | 844 |
105 | 102 | 101 | 104 | 104 | 113 | 111 | 112 | 151 | 165 | 182 | 222 | |
CWIP | 20 | 1 | 3 | 6 | 10 | 24 | 30 | 43 | 36 | 70 | 97 | 99 |
Investments | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
174 | 172 | 160 | 187 | 201 | 214 | 229 | 284 | 425 | 415 | 465 | 522 | |
Total Assets | 299 | 275 | 264 | 298 | 315 | 351 | 370 | 439 | 611 | 650 | 743 | 844 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
3 | 46 | 29 | 16 | 26 | 25 | 31 | 60 | -33 | 34 | 43 | 42 | |
-9 | -10 | -9 | -18 | -11 | -25 | -13 | -25 | -84 | -13 | -44 | -56 | |
7 | -37 | -19 | 2 | -15 | -1 | -18 | -35 | 123 | -20 | 1 | 26 | |
Net Cash Flow | 0 | -0 | 0 | -0 | -0 | -0 | 0 | 0 | 5 | 2 | 1 | 11 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 68 | 91 | 70 | 86 | 75 | 88 | 94 | 89 | 97 | 108 | 126 | 125 |
Inventory Days | 103 | 78 | 119 | 122 | 138 | 129 | 154 | 121 | 202 | 133 | 126 | 153 |
Days Payable | 69 | 119 | 115 | 95 | 118 | 90 | 95 | 104 | 84 | 89 | 103 | 108 |
Cash Conversion Cycle | 101 | 50 | 74 | 113 | 96 | 127 | 153 | 106 | 215 | 152 | 149 | 170 |
Working Capital Days | 108 | 67 | 80 | 109 | 121 | 117 | 126 | 113 | 200 | 177 | 180 | 189 |
ROCE % | 14% | 14% | 14% | 19% | 14% | 16% | 14% | 30% | 21% | 8% | 14% | 10% |
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
1d - Kopran's Annual Secretarial Compliance Report for FY 2025 shows full regulatory compliance, no major violations.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 16 May
-
Announcement under Regulation 30 (LODR)-Investor Presentation
15 May - Investor Presentation on Financial Result for the FY 2024-25
-
Board Meeting Outcome for Final Dividend For FY 2024-25
15 May - Kopran Ltd reports audited FY25 results; declares Rs.3 dividend subject to shareholder approval.
-
Board Meeting Outcome for Final Dividend For FY 2024-25
15 May - Kopran Ltd reports audited FY25 results with Rs.3 dividend, approved by board, subject to shareholder nod.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
May 2025TranscriptNotesPPT
-
Mar 2025TranscriptPPT
-
Feb 2025TranscriptPPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT REC
-
Aug 2024TranscriptPPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
May 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
Business Verticals FY24
1. API Vertical (~54%): WOS Kopran Research Laboratories operates the API vertical. [1] The co. undertakes development, manufacturing, and sale of diverse Active Pharmaceutical Ingredients and Advanced Intermediates. It is one of the leaders in Atenolol. [2]